Nov 8 (Reuters) - Poxel SA POXEL.PA :
* AS OF SEPTEMBER 30, 2023, CASH AND CASH EQUIVALENTS WERE
EUR 5.3
MILLION (USD 5.6 MILLION)
* ASSUMING FULL DRAWDOWN OF EXISTING EQUITY-LINKED FINANCING
FACILITY WITH IRIS, CASH RUNWAY THROUGH Q2 2025
* POXEL REPORTED REVENUES OF EUR 1,619 THOUSAND FOR NINE
MONTHS
ENDED SEPTEMBER 30, 2023,
* COMPANY EXPECTS THAT ITS RESOURCES WILL BE SUFFICIENT TO
FUND
ITS OPERATIONS AND CAPITAL EXPENDITURE REQUIREMENTS UNTIL
JANUARY 2024
* FOR TERRITORIES NOT COVERED BY ITS AGREEMENT WITH SUMITOMO
PHARMA, POXEL IS HAVING ACTIVE DISCUSSIONS WITH VARIOUS
POTENTIAL PARTNERS FOR IMEGLIMIN, IN SEVERAL COUNTRIES
Source text for Eikon: ID:nBwbVWpdKa
Further company coverage: POXEL.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))